Metabolic effects of statins and clinical manifestations of atherosclerosis

Russian Journal of Cardiology

Volumn 94, Issue 2, 2012, Pages 85-90

  Yakovenko, E I ^a   Mamedov, M N ^b  

^a State Research Centre for Preventive Medicine ^*  (Russian Federation)

^b NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

Atherosclerosis; Metabolic effects; Statins

Indexed keywords

EID: 84933036664     PISSN: 15604071     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Diagnostics and correction of infringements lipid an exchange for the purpose of preventive maintenance and atherosclerosis treatment. National clinical guidelines 2th ed. Silicea-Polygraf, Moscow 2009, p.528. Russian
2. Оgаnоv R. G. Demographic situation and cardiovascular diseases in Russia: ways of the decision of problems. Cardiovascular therapy and prevention 2007; 6 (8):7–14. Russian.
3. All about cholesterol. The national report; under edition RAMN L. A. Bokerija i akademika RAMN R. G. Oganova.- Moscow: NCSSH im. A. N. Bakuleva RAMN, 2010. Russian.
4. Mamedov MN. Diagnostics, preventive maintenance and treatment of a diabetes and its complications (on materials ХХ World congress the International Federation of the Diabetes) Moscow: OOO RG «PRE100» 2010. Russian.
5. Alderman M. H. Serum Uric Acid As a Cardiovacular Risk Factor for Hart Disease. Current Hypertension Reports 2001; 3:184–189.
6. Steinberg D. The LDL modification hypothesis of aterogenesis: an update. J. Lipid Res. 2009; Suppl: 376–381.
7. Ignarro IJ, Lun W. Nitric oxide in the regulation of vascular function: an historical overview J Card Surg. 2002;17 (4): 301–306.
8. Ragino J. I. et al. Key laboratory-diagnostic biomarkers of a coronary atherosclerosis. Cardiology 2011; 3 (51):42–46. Russian
9. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008; 79 (3): 360–376.
10. Tatenkulova S. N., Belenkov Ju. N., Mareev V. Ju. et al. Influence statins on immune mechanisms of inflammatory reaction at CHF and an ischemic etiology. Serdechnaja nedostatochnost 2009; 10, № 2 (52):107–114. Russian.
11. Susekov A. V. Inhibitors GMK-KoA-reduktazy at secondary preventive maintenance of an atherosclerosis: 30 years later. Dislipidemia and atherosclerosis 2005; 7 (11):17–26. Russian.
12. Konstantinov V. A, Kuharchuk G. A. et al. Blood Lipids, an inflammation and an atherosclerosis – a new view on preventive maintenance in the light of results of recent clinical researches. Heart. 2009; 8 № 5 (49): 240–242. Russian.
13. Astra Zeneka: Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit [press release] March 31, 2008.
14. Hanefeld M., Marx N., Pfutzner A. et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C‑reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007; 23; 49 (3):290–7.
15. Devaraj S, Chan ЕJ. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006; 91 (11):4489–96.
16. Ridker PM, Danielson E, Fonseka FA. et al. Rosuvastatin to prevent vascular events in men and women with elevated C‑reactive protein. N Engl J Med. 2008; 359 (21):2195–2207.
17. Lee SJ, Qin H, Benveniste EN. The IFN- gamma-induced transcriptional program of the CIITA gene in inhibited by statins. Eur J Immunol. 2008; 38 (8):2325–2336.
18. Heeba G, Hassan MK, Khalifa M, et al. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc. Pharmacol. 2007; 50 (4): 391–398.
19. Singh U, Deveraj S, Jialal I. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008; 102 (3): 321–5.
20. Schwartz R, Osborne-Lawrence S, Hahner L et al. C‑reactive protein downrequlates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007; 100 (10): 1452–1459.
21. Strey CH, Young JM, Lainchbury JH, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heat. 2006; 92 (11): 1603–1609.
22. Arutyunov G.P, Bylova N. A., Dzidzarija M. I. A insulinrezistens syndrome and HF – an unresolved problem. Serdechnaja nedostatochnost. 2009; 10, 3 (53):177–182.Russian
23. Rugina M, Caras I, Jurcut R, et al. Sistemic inflammatory markers in patients with aortic sclerosis. Roum Arch Microbiol Immunol. 2007; 66 (1–2):10–16.
24. Ferrari LA, Mancini M, Celentano A, et al. Early changes of the arterial carotid wall in hyperinsulinemia, hypertriglyceridemia, versus hyperholesterolemia. Aterosclerosis 2003; 171 (2): 303–309.
25. Mamedov M.N, Oganov R. G. Postprandial hyperglycemia – a target for preventive maintenance of cardiovascular complications and a diabetes. Moscow: RPK «Vikas – print» 2010. Russian.
26. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57 (14): 1535–45.
27. Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010; 55 (12):1209–16.
28. Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old question and new insights. FEBS Lett. 2005; 579:295–30.
29. Scherer PE. Adiponectin: its multiple roles. Diabetes UK, Diabetic Medicine. 2006; 23 (4):43.
30. Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. AM J Kidney Dis. 1999; 33:225–234.
31. Lewandowski J, Sinski M, Bidiuk J, et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens Res. 2010; 33 (10):1038–43.
32. Сrouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA. 2007; 2979120: 1344–1353.
33. Messerli FH, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapya – meta-analysis. Am J Cardiol. 2008; 101 (3): 319–25.